Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Investors: Take Advantage of Double Fed Tax Credits on Critical Minerals Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Healthcare Biotechnology
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:FRX)

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 9, 2023

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 6, 2023

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

GlobeNewswire October 30, 2023

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire September 7, 2023

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 3, 2023

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

GlobeNewswire July 31, 2023

Fennec Announces Results of Annual Meeting

GlobeNewswire June 12, 2023

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi(TM) (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

GlobeNewswire June 6, 2023

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 11, 2023
View More News ››

Opinion & Analysis (TSX:FRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:FRX)

RE:Pedmark approved

Pedmark commercially available as of today!!! Great news for everyone involved..investors and patients alike.
willyk3 - October 17, 2022

Pedmark approved

by the US FDA.    Finally!!!! Now ....about that takeout??
willyk3 - September 21, 2022

Fennec Pharmaceuticals Up to $45 M Investment From Petrichor

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential...
Betteryear2 - August 1, 2022

RE:RE:IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

The obvious solution at this stage is to just sell the darn company (at a discount) to a real pharmaceautical company who  has the...
willyk3 - December 13, 2021

RE:IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

Absolute dud    The fact that they failed at the manufacturing revisions shows that they and their mfg partner  are...
willyk3 - December 9, 2021

IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

$FENC  Fennec Pharmaceuticals (NASDAQ:FENC), a "specialty pharmaceutical company", received a CRL from the FDA for...
AviseAnalytics - December 9, 2021
View more Bullboard ››

Pulsar Helium Inc.

Pulsar Helium Inc.

Pulsar Helium Inc. is a Canada-based helium exploration and development company. The Company's assets include the flagship ...
View More »